Nasdaq
Key information relating to the preferential rights issue to be carried out by PCI Biotech Holding ASA
24-08-2018
| Date on which the terms and conditions of the preferential rights issue were announced: 24 august 2018 |
| Last day including right: 14 September 2018 |
| Ex-date: 17 September 2018 |
| Record Date: 18 September 2018 |
| Date of approval: 14 September 2018 |
| Maximum number of new shares: 12,000,000 |
| Subscription price: 30 |
| Will the rights be listed: yes |
| This information is published in accordance with the requirements of the Continuing Obligations. |
Latest Health & Supplement Reviews
- YuSleep Reviews (EXPOSED) Doctor Explains Deep Sleep Benefits, Hidden Risks & Real Consumers Results In 2026
- Neuro Energizer Reviews and Complaints 2026: How This Neuro-Sonic Breakthrough Is Reshaping Cognitive Therapy, Memory & Daily Focus
- Gluco6 Reviews and Complaints (March 2026) Real User Data on Natural Blood Sugar Balance and Glucose Stability